Publikationen in Zusammenarbeit mit Forschern von Heidelberg University (30)

2023

  1. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

    Bone Marrow Transplantation, Vol. 58, Núm. 11, pp. 1182-1188

  2. Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors

    Hematological Oncology, Vol. 41, Núm. 4, pp. 631-643

  3. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

  4. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

  5. Severe cytopenia after CD19 CAR T-cell therapy: A retrospective study from the EBMT Transplant Complications Working Party

    Journal for ImmunoTherapy of Cancer, Vol. 11, Núm. 4

2022

  1. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT

    Blood Cancer Journal, Vol. 12, Núm. 9

  2. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

    Blood, Vol. 140, Núm. 21, pp. 2248-2260

2021

  1. Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial

    Bone Marrow Transplantation, Vol. 56, Núm. 6, pp. 1413-1421

2020

  1. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP-EBMT study

    British Journal of Haematology, Vol. 188, Núm. 5, pp. 745-756

2019

  1. Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016

    British Journal of Haematology

  2. Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study

    Leukemia and Lymphoma, Vol. 60, Núm. 7, pp. 1803-1811

  3. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

    European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973

  4. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 4, pp. 1125-1133.e1

2018

  1. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis

    Blood Advances, Vol. 2, Núm. 18, pp. 2400-2411

  2. Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

    Leukemia, Vol. 32, Núm. 7, pp. 1542-1560

2017

  1. Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci

    Nature Genetics, Vol. 49, Núm. 7, pp. 993-1004

  2. High-dose therapy and autologous stem cell transplantation in patients with poems syndrome: A retrospective study of the plasma cell disorder sub-committee of the chronic malignancy working party of the European society for blood & marrow transplantation

    Haematologica, Vol. 102, Núm. 1, pp. 160-167

  3. Identification of miRSNPs associated with the risk of multiple myeloma

    International Journal of Cancer, Vol. 140, Núm. 3, pp. 526-534

  4. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 28, pp. iv52-iv61

2016

  1. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis

    Oncotarget, Vol. 7, Núm. 37, pp. 59029-59048